NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update
Portfolio Pulse from
NewAmsterdam Pharma has released its full-year 2024 financial results and provided a corporate update. The company expects an EMA submission in the second half of 2025 through its partner Menarini. Additional data from its BROADWAY, BROOKLYN, and TANDEM studies will be presented throughout 2025.
February 26, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
NewAmsterdam Pharma has announced its 2024 financial results and plans for an EMA submission in 2025. The company will also present additional data from key studies next year.
The announcement of financial results and future plans for EMA submission and data presentations are significant for NewAmsterdam Pharma. However, the impact on the stock price is neutral in the short term as these events are scheduled for the future.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100